title: Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
authors.affiliation: Department of Clinical Neuroscience, University of Götenborg, Sweden.
authors.forename: O
authors.initials: O
authors.lastname: Andersen
authors.forename: J
authors.initials: J
authors.lastname: Lycke
authors.forename: P O
authors.initials: PO
authors.lastname: Tollesson
authors.forename: A
authors.initials: A
authors.lastname: Svenningsson
authors.forename: B
authors.initials: B
authors.lastname: Runmarker
authors.forename: A S
authors.initials: AS
authors.lastname: Linde
authors.forename: M
authors.initials: M
authors.lastname: Aström
authors.forename: P
authors.initials: P
authors.lastname: Gjörstrup
authors.forename: S
authors.initials: S
authors.lastname: Ekholm
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D006912:Hydroxyquinolines / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D006912:Hydroxyquinolines; C045282:roquinimex